Higashikagawa, Japan

Takahiro Tanimoto

This inventor holds 7 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Medrx Co., Ltd. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takahiro Tanimoto. Retrieved from https://idiyas.com/inventor/takahiro-tanimoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 100.0


 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Higashikagawa, JP (2013 - 2023)
  • Kagawa, JP (2018 - 2024)

Company Filing History:


Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Takahiro Tanimoto

Introduction

Takahiro Tanimoto is a notable inventor based in Higashikagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of transdermal patch preparations. With a total of 7 patents to his name, Tanimoto's work has the potential to improve patient care and treatment efficacy.

Latest Patents

One of Tanimoto's latest patents is a composition for patch preparation that includes a drug, organic solvent, lipophilic mass base, and powder. This non-aqueous patch preparation features a drug solution where the drug is dissolved in an organic solvent, combined with a lipophilic mass base and anhydrous silicic acid powders. The organic solvent is selected from options such as propylene glycol, 1,3-butanediol, polyethylene glycol, and propylene carbonate. The lipophilic mass base consists of an elastomer, a tackifier, and a softening agent, specifically utilizing styrene-isoprene-styrene copolymer (SIS). The formulation contains 2% to 10% by weight of the anhydrous silicic acid powders.

Another significant invention by Tanimoto is a tizanidine therapy system. This invention aims to provide a method for treating patients suffering from spasticity. It involves administering a modified release dosage form containing tizanidine or a pharmaceutically acceptable salt thereof. The transdermal patch preparation is designed to release between 4 mg to 36 mg of tizanidine over a period of at least 24 hours.

Career Highlights

Takahiro Tanimoto is currently associated with Medrx Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on enhancing drug delivery systems, which can lead to better therapeutic outcomes for patients.

Collaborations

Tanimoto has collaborated with notable colleagues such as Hidetoshi Hamamoto and Katsuhiro Yamanaka. Their combined expertise contributes to the advancement of innovative solutions in the field of pharmaceuticals.

Conclusion

Takahiro Tanimoto's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving patient care. His work in developing advanced drug delivery systems is paving the way for more effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…